LEXX - Lexaria Bioscience Corp

LEXX - Lexaria Bioscience Corp

https://lexariabioscience.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Lexaria Bioscience Corp. ( NASDAQ: LEXX ) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

GlobeNewswire • 1 year, 8 months ago • score: 0.57

NEW YORK, Jan. 11, 2024 ( GLOBE NEWSWIRE ) -- NetworkNewsAudio - Lexaria Bioscience Corp. ( NASDAQ: LEXX ) announces the availability of a broadcast titled, "Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs." ...

Lexaria Bioscience Corp. ( NASDAQ: LEXX ) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

GlobeNewswire • 1 year, 10 months ago • score: 0.25

NEW YORK, Oct. 31, 2023 ( GLOBE NEWSWIRE ) -- via InvestorWire - Lexaria Bioscience Corp. ( NASDAQ: LEXX ) today announces its placement in an editorial published by NetworkNewsWire ( "NNW" ) , one of 60+ brands within the Dynamic Brand Portfolio @ IBN ( InvestorBrandNetwork ) , a specialized ...

Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases - Lexaria Bioscience ( NASDAQ:LEXX )

Benzinga • 2 years, 3 months ago • score: 0.24

Lexaria Bioscience Corp LEXX LEXXW announced additional findings from last year's human clinical Study HYPER-H21-4 demonstrating significant reductions in several pro-inflammatory biomarkers known to be linked to cardiovascular disease ( CVD ) .

Study Shows Significant Improvements In Peak Bloodstream Estradiol Delivery Using Lexaria's DehydraTECH - Lexaria Bioscience ( NASDAQ:LEXX )

Benzinga • 2 years, 3 months ago • score: 0.51

Lexaria Bioscience Corp LEXX announces that its animal study HOR-A22-1 has been completed, showing significant enhancement in the oral delivery of the estrogen hormone estradiol.

$1M Bet On Glatfelter? Check Out These 4 Penny Stocks Insiders Are Buying - Lexaria Bioscience ( NASDAQ:LEXX ) , Glatfelter ( NYSE:GLT )

Benzinga • 2 years, 6 months ago • score: 0.45

The Dow Jones closed lower by over 70 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Lexaria Bioscience Corp. The company is headquartered in Kelowna, Canada.

52W High

$3.72

52W Low

$0.78

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.86

Valuation

As of 2025-05-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-7.22

EV/Revenue (<3 favorable)

25.39

P/S (TTM) (<3 favorable)

32.71

P/B (<3 favorable)

3.63

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

7.14%

Institutions (25–75% balanced)

11.75%

Shares Outstanding

19,559,200

Float

16,946,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-05-31 (Overview)

Revenue (TTM)

615,920

Gross Profit (TTM)

613,200

EPS (TTM)

-0.68

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-21.55%

ROE (TTM) (>15% strong)

-1.53%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

1.07

Momentum

Bearish momentum

Value

0.0705

Previous

0.0520

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025